[Modern pharmacotherapy of age-related macular degeneration].
Age-related macular degeneration (AMD) is now the most common cause for blind registration in all developed countries. Epidemiologic data indicate that there are 4.5 millions affected in Germany with constant increase in incidence and prevalence with subsequent considerable health economic implications. Late manifestations of the disease result in the inability to read and to perform daily tasks. Therefore, there is an urgent need for efficacious prophylactic and therapeutic measures to prevent irreversible loss of central vision. Based on a better understanding of the underlying molecular mechanisms new therapeutic approaches have been brought forward and expand previous approaches such as thermal laser surgery or photodynamic therapy. Repeated intravitreal injection of anti-VEGF (vascular endothelial growth factor) agents as well as corticosteroids have a beneficial effect on growth and permeability of neovascular membranes. The risk for progression from early to late stages of AMD can be reduced with certain antioxidative preparations (AREDS medication) in presence of defined funduscopic signs. Early diagnosis is key for all currently available interventions since a beneficial effect can only be achieved in early stages of the disease process.
Holz
F G
FG
Universitäts-Augenklinik, Bonn. frank.holz@ukb.uni-bonn.de
Helb
H M
HM
Bindewald-Wittich
A
A
Scholl
H P N
HP
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D042501:Angiogenic Proteins / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends*; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D042501:Angiogenic Proteins; D000975:Antioxidants; D042461:Vascular Endothelial Growth Factor A